FIELD: chemistry.
SUBSTANCE: invention relates to crystalline form of N-[(R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide, where crystalline form represents polymorphic form IV which has roentgen powder difractogram with characteristic peaks, expressed in degrees 2θ,approximately at 4.6, 7.2, 14.6, 19.9, 23.2 and 26.5. Invention also relates to pharmaceutical composition, dosed form, method of obtaining polymorphic form IV and to method of treating disease state, mediated by MEK activity.
EFFECT: increase of target product output.
17 cl, 1 tbl, 1 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL][3-HYDROXY-3-(PIPERIDINE-2-YL)AZETIDINE-1-YL]METHANONE | 2016 |
|
RU2762181C2 |
| BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | 2009 |
|
RU2509078C2 |
| HETEROCYCLIC MEK INHIBITORS AND METHODS OF USING THEREOF | 2006 |
|
RU2414455C2 |
| QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
| N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
| N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2722560C1 |
| NOVEL CONDENSED PYRIDINE DERIVATIVES USED AS C-MET TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619130C2 |
| 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | 2009 |
|
RU2515612C2 |
| COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS FOR USE OF SAID COMPOUNDS AND METHODS | 2008 |
|
RU2487121C2 |
| SOLID FORMS OF (R)-1-(2, 2-DIFLUOROBENZO[D][1, 3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE | 2011 |
|
RU2711481C2 |
